Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease.

Katsumoto TR, Violette SM, Sheppard D.

Int J Rheumatol. 2011;2011:208219. doi: 10.1155/2011/208219. Epub 2011 Oct 16.

2.

Interstitial lung disease in systemic sclerosis.

Bussone G, Mouthon L.

Autoimmun Rev. 2011 Mar;10(5):248-55. doi: 10.1016/j.autrev.2010.09.012. Epub 2010 Sep 21. Review.

PMID:
20863911
3.

Genetic Susceptibility to Interstitial Lung Disease Associated with Systemic Sclerosis.

Tochimoto A, Kawaguchi Y, Yamanaka H.

Clin Med Insights Circ Respir Pulm Med. 2016 Mar 13;9(Suppl 1):135-40. doi: 10.4137/CCRPM.S23312. eCollection 2015. Review.

4.

Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence.

Christmann RB, Wells AU, Capelozzi VL, Silver RM.

Semin Arthritis Rheum. 2010 Dec;40(3):241-9. doi: 10.1016/j.semarthrit.2010.03.002. Epub 2010 May 21. Review.

PMID:
20494406
5.

BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis.

Meloni F, Caporali R, Marone Bianco A, Paschetto E, Morosini M, Fietta AM, Patrizio V, Bobbio-Pallavicini F, Pozzi E, Montecucco C.

Sarcoidosis Vasc Diffuse Lung Dis. 2004 Jun;21(2):111-8.

PMID:
15281432
6.

Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide.

Tourkina E, Bonner M, Oates J, Hofbauer A, Richard M, Znoyko S, Visconti RP, Zhang J, Hatfield CM, Silver RM, Hoffman S.

Fibrogenesis Tissue Repair. 2011 Jul 1;4(1):15. doi: 10.1186/1755-1536-4-15.

7.

Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease.

Xiao H, Zhang GF, Liao XP, Li XJ, Zhang J, Lin H, Chen Z, Zhang X.

Int J Rheum Dis. 2018 Feb;21(2):477-486. doi: 10.1111/1756-185X.13247. Epub 2018 Jan 7.

PMID:
29316328
8.

Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.

Gonzalez-Lopez L, Rocha-Muñoz AD, Olivas-Flores EM, Garcia-Gonzalez A, Peguero-Gómez AR, Flores-Navarro J, Villa-Manzano AI, Zavaleta-Muñiz SA, Salazar-Paramo M, Mejía M, Juárez-Contreras P, Vazquez-Del Mercado M, Cardona-Muñoz EG, Trujillo-Hernández B, Nava-Zavala AH, Gamez-Nava JI.

Arch Bronconeumol. 2015 Sep;51(9):440-8. doi: 10.1016/j.arbres.2014.06.018. Epub 2014 Oct 7. English, Spanish.

9.

[Use of pulmonary function tests and biomarkers studies to diagnose and follow-up interstitial lung disease in systemic sclerosis].

Hua-Huy T, Rivière S, Tiev KP, Dinh-Xuan AT.

Rev Pneumol Clin. 2014 Dec;70(6):335-42. doi: 10.1016/j.pneumo.2014.09.003. Epub 2014 Nov 20. Review. French.

PMID:
25457218
10.

Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage.

Manetti M, Guiducci S, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M.

Ann Rheum Dis. 2012 Jun;71(6):1064-72. doi: 10.1136/annrheumdis-2011-200837. Epub 2012 Jan 17.

PMID:
22258486
11.

Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis.

Andersen GN, Nilsson K, Pourazar J, Hackett TL, Kazzam E, Blomberg A, Waldenström A, Warner J, Rantapää-Dahlqvist S, Mincheva-Nilsson L, Sandström T.

Respir Med. 2007 Oct;101(10):2199-206. Epub 2007 Jul 20.

12.

[Interstitial lung disease in systemic sclerosis].

Mouthon L, Berezné A, Brauner M, Kambouchner M, Guillevin L, Valeyre D.

Rev Mal Respir. 2007 Oct;24(8):1035-46. Review. French.

13.

Therapeutic options for systemic sclerosis related interstitial lung diseases.

Mouthon L, Bérezné A, Guillevin L, Valeyre D.

Respir Med. 2010 Jul;104 Suppl 1:S59-69. doi: 10.1016/j.rmed.2010.03.018.

14.

Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.

Guarnieri G, Zanatta E, Mason P, Scarpa MC, Pigatto E, Maestrelli P, Cozzi F.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S80-6. Epub 2015 Apr 16.

PMID:
25897784
15.

Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q).

Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, McAnulty RJ, Sheppard D, Jenkins G.

Am J Pathol. 2009 Apr;174(4):1264-79. doi: 10.2353/ajpath.2009.080160. Epub 2009 Jan 15.

16.

Pathogenesis and therapeutics of interstitial lung disease in systemic sclerosis.

Castillo-Tandazo W, González J, Flores-Fortty A.

Curr Rheumatol Rev. 2013;9(2):105-12.

PMID:
25409668
17.

Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease.

Lee R, Reese C, Bonner M, Tourkina E, Hajdu Z, Riemer EC, Silver RM, Visconti RP, Hoffman S.

Am J Physiol Lung Cell Mol Physiol. 2014 Apr 15;306(8):L736-48. doi: 10.1152/ajplung.00210.2013. Epub 2014 Feb 28.

18.

Coagulation and autoimmunity in scleroderma interstitial lung disease.

Ludwicka-Bradley A, Silver RM, Bogatkevich GS.

Semin Arthritis Rheum. 2011 Oct;41(2):212-22. doi: 10.1016/j.semarthrit.2010.10.002. Epub 2010 Dec 17. Review.

19.

Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature.

Stock CJW, Renzoni EA.

Eur J Hum Genet. 2018 Feb 23. doi: 10.1038/s41431-018-0104-8. [Epub ahead of print]

PMID:
29476163
20.

[Interstitial lung disease in systemic sclerosis].

Mouthon L, Berezné A, Brauner M, Kambouchner M, Guillevin L, Valeyre D.

Presse Med. 2006 Dec;35(12 Pt 2):1943-51. Review. French.

PMID:
17159721

Supplemental Content

Support Center